A Study in Rheumatoid Arthritis Patients Who Have Completed a Preceding Study With ABBV-105 Given Alone or in Combination With Upadacitinib

PHASE2

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped Study M16-763 was terminated early as the benefit of each treatment arm from the feeder study (Study M16-063) did not provide appreciable evidence of differentiated clinical effect to warrant further long-term continuation.

Conditions

Rheumatoid Arthritis (RA)

Interventions

DRUG: Elsubrutinib
DRUG: Upadacitinib
DRUG: Placebo for elsubrutinib
DRUG: Placebo for upadacitinib

Sponsor

AbbVie